ClinicalTrials.gg
RecruitingNCT06285318REALiTEC/TALUpdated Aug 28, 2026

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

An observational study in Relapsed/Refractory Multiple Myeloma (RRMM), sponsored by Janssen-Cilag Ltd.. Recruiting at 68 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Janssen-Cilag Ltd. (part of Johnson & Johnson) · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
900
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 126 studies in Multiple Myeloma by Johnson & Johnson — 13 open to participants now, 33 under way, 12 of them phase 3. Multiple Myeloma · Johnson & Johnson.

Planned enrollment
5th of 18
900 · median 255
Started
2023
with 1 other
Observational
18 of 126
1 open now
Primary completion
2026-08
later than 9 of 32 live
Registered
111th of 126
by date

Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 5th largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2023, is one of 18 observational ones, reaches primary completion later than 9 of the 32 other live ones, and was the 111th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 126 studies in Multiple Myeloma by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Multiple Myeloma by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma (RRMM)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population include patients who have initiated the treatment with T-cell redirectors outside of a clinical trial setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a documented diagnosis of multiple myeloma
  • Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts
  • Received at least one dose of teclistamab/talquetamab
  • Provision of a patient-signed form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements

Exclusion criteria

Exclusion Criteria:

  • To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
  • To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
  • Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
900 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort 1

    Participants with RRMM who received at least one dose of teclistamab outside of clinical trials on or before 31 December 2022 will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.

    Other: Teclistamab

  • Participants with Relapsed/Refractory Multiple Myeloma (RRMM): Teclistamab Cohort 2

    Participants with RRMM who received at least one dose of teclistamab outside of clinical trials from 01 January 2023 to 31 December 2024, inclusive will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.

    Other: Teclistamab

  • Participants with RRMM: Teclistamab Cohort 3

    Participants with RRMM who received at least one dose of teclistamab outside of clinical trials from 01 January 2025 to 31 December 2025, inclusive will be enrolled in the study. The data available from the medical records of each enrolled participant will be the collected to describe the use of teclistamab.

    Other: Teclistamab

  • Participants with RRMM: Talquetamab Cohort

    Participants with RRMM who received at least one dose of talquetamab outside of clinical trials on or before 31 December 2023 will be enrolled in the study. The data available from the medical records of each enrolled participant will be collected to describe the use of talquetamab.

    Other: Talquetamab

Interventions

  • OtherTeclistamab

    No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.

    Also known as: TECVAYLI

  • OtherTalquetamab

    No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.

    Also known as: TALVEY

06

What researchers measure

Primary outcomes

  1. Describe Baseline Characteristics of Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who Received Teclistamab/ Talquetamab Outside of Clinical Trials

    Participants' demographics and disease characteristics (age, co-morbidities, renal function), and prior antimyeloma therapies will be reported.

    Time frame: Baseline (Day 1)

  2. Overall Response Rate (ORR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    ORR is defined as the percentage of patients who have a PR or better as assessed by investigator per International Myeloma Working Group (IMWG) response criteria.

    Time frame: Up to 40 months

  3. Time to First Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    Time to first response is defined as the time between date of first dose of teclistamab/talquetamab and the date when patient has achieved first response, as assessed by investigator per IMWG response criteria.

    Time frame: Up to 40 months

  4. Time to Best Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    Time to best response is defined as the time between date of first dose of teclistamab/talquetamab and the date of the best response, as assessed by investigator per IMWG response criteria.

    Time frame: Up to 40 months

  5. Duration of Response (DOR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    DOR will be calculated among participants (with a PR or better response) from the date of the first response (PR or better) to the date of first evidence of progressive disease, as assessed by investigator per IMWG response criteria.

    Time frame: Up to 40 months

  6. Minimal Residue Assessment (MRD) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    Number of participants with MRD negative rate will be assessed.

    Time frame: Up to 40 months

  7. Overall Survival (OS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    OS is defined as the time from the date of first dose of teclistamab/talquetamab to the date of the participant's death.

    Time frame: From the date of first dose of teclistamab/talquetamab to the date of the participant's death (up to 40 months)

  8. Progression Free Survival (PFS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    PFS is defined as the time from the date of first dose of teclistamab/talquetamab to the date of first evidence of progressive disease, as assessed by investigator per IMWG response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to 40 months

  9. Time to Next Treatment (TTNT) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials

    TTNT is defined as the time from the date of first dose of teclistamab/talquetamab to the start of the next line of antimyeloma treatment.

    Time frame: Up to 40 months

  10. Describe the Safety Management of Teclistamab/Talquetamab in the Treatment of Participants with RRMM Outside of Clinical Trials

    Incidence and severity of adverse events (AEs) including immune effector cell-associated neurotoxicity syndrome (ICANS), cytokine release syndrome (CRS) and other AEs as well as medications used for prophylaxis and management of adverse events will be reported.

    Time frame: Baseline (Day 1) up to end of treatment (up to 40 months)

Secondary outcomes

  1. Describe the Use of Teclistamab/Talquetamab in the Treatment of Participants with RRMM Outside of Clinical Trials

    Treatment patterns including healthcare setting and treatment schedules will be reported.

    Time frame: Baseline (Day 1) up to end of treatment (up to 40 months)

07

Study locations

29 of 68 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Aug 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Feb 29, 2024
StartActual
Dec 18, 2023
Primary completionEst.
Aug 30, 2026
CompletionEst.
Sep 24, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06285318
Lead sponsor
Janssen-Cilag Ltd.
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Dec 18, 2023
Primary completion
Aug 30, 2026 (estimated)
Completion
Sep 24, 2026 (estimated)
Last update
Aug 28, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen-Cilag Limited Clinical Trial
study director · Janssen-Cilag Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion